Analyst firms · Wolfe Research · TEAM
Wolfe Research TEAM price target and rating history
Atlassian Corporation (TEAM) · Technology
Wolfe Research rates Atlassian Corporation (TEAM) Outperform with a $500 price target, as of its latest action on Oct 29, 2021. It has published 3 rating actions on TEAM since August 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a TEAM price target in the last 12 months, the median target is $175.
- Current rating
- Outperform
- Price target
- $500
- Median target, all firms
- $175
- Actions on TEAM
- 3
Wolfe Research price target on TEAM
Every Wolfe Research rating on TEAM
- Oct 29, 2021
- Aug 31, 2021
- Aug 30, 2021
How other firms rate TEAM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| RBC Capital Markets | Outperform | $215 | Aug 26, 2026 |
| BofA Securities | Buy | $175 | Aug 7, 2026 |
| BMO Capital Markets | Outperform | $175 | Aug 7, 2026 |
| BNP Paribas Exane | Outperform | $95 | Mar 16, 2026 |
| BTIG | Buy | $220 | Dec 17, 2025 |
Questions about Wolfe Research and TEAM
- What is Wolfe Research's price target for TEAM?
- Wolfe Research's latest stated price target for Atlassian Corporation (TEAM) is $500, from its action on Oct 29, 2021.
- What is Wolfe Research's rating on TEAM?
- Wolfe Research rates TEAM Outperform, a bullish rating, as of Oct 29, 2021.
- When did Wolfe Research last change its view on TEAM?
- On Oct 29, 2021, Wolfe Research raises its price target to $500 from $400, keeps Outperform.
- How does Wolfe Research's TEAM target compare with other analysts?
- Across 5 firms with a TEAM price target in the last 12 months, the median target is $175.
More TEAM rating histories
- BMO Capital Markets12
- Capital One3
- Robert W. Baird3
- Macquarie3
- Truist Securities3
- KeyBanc Capital Markets3
- Goldman Sachs4
- Piper Sandler4
- TD Cowen6
- Mizuho4
All Wolfe Research ratingsTEAM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.